BIRC5 and neoplasm: Among them, the small molecule YM155 came out of a high-throughput screening for inhibitors of survivin promoter activity and phase I clinical trials using this compound, conducted in heavily pretreated cancer patients provided evidence that an objective tumor response could be achieved in some cases with an overall favorable toxicity profile.